Cite
Phase III/IV, Randomized, Fifty‐Two–Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus.
MLA
Ginzler, Ellen, et al. “Phase III/IV, Randomized, Fifty‐Two–Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus.” Arthritis & Rheumatology, vol. 74, no. 1, Jan. 2022, pp. 112–23. EBSCOhost, https://doi.org/10.1002/art.41900.
APA
Ginzler, E., Guedes Barbosa, L. S., D’Cruz, D., Furie, R., Maksimowicz, M. K., Oates, J., Santiago, M. B., Saxena, A., Sheikh, S., Bass, D. L., Burriss, S. W., Gilbride, J. A., Groark, J. G., Miller, M., Pierce, A., Roth, D. A., & Ji, B. (2022). Phase III/IV, Randomized, Fifty‐Two–Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus. Arthritis & Rheumatology, 74(1), 112–123. https://doi.org/10.1002/art.41900
Chicago
Ginzler, Ellen, Luiz Sergio Guedes Barbosa, David D’Cruz, Richard Furie, McKinnon, Kathleen Maksimowicz, James Oates, Mittermayer Barreto Santiago, et al. 2022. “Phase III/IV, Randomized, Fifty‐Two–Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus.” Arthritis & Rheumatology 74 (1): 112–23. doi:10.1002/art.41900.